Application General

eBS Logo

Product Name:	Eir Women Zipped
Product Code:	Other products
Client Name:	Ellkay Group Pty Ltd
Sponsor Name:	Ellkay Group Pty Ltd
Is this Application in response to a Section 30:	No
Can this product be used as a code stock:	No
This application is to:	change a current ARTG Entry
AUST L:	386951
Submission Cost:	$0.00
Payment Exemption No:	
Application Status:	Completed
Application Type:	Correction of ARTG Record
Validation Report:	24/08/2023 7:07:02 PM

Information Messages

Successful validation of this application is not to be considered as an indication that a medicine is compliant with the legislative requirements. The listed medicines validation system is a tool to assist sponsors in listing a medicine on the ARTG. Sponsors are expected to be aware of, and comply with, all relevant regulatory requirements for their listed medicine.

s47

Gluten is a mandatory component of Maltodextrin where the ingredient is derived from gluten containing grains such as wheat, barley, rye and oats and must be declared in the application when the route of administration is other than Topical and Mucosal. Medicines containing gluten require the label statement GLUTEN 'Contains [insert name of

ingredient]'. (Ingredient(s) concerned: 'Maltodextrin')

Chromium sourced from organic materials: Medicines are listable only if the maximum recommended daily dose provides 50 micrograms or less of chromium from organic sources (ie chromium picolinate, chromium nicotinate and 'High chromium yeast'). Chromium sourced from inorganic materials: listable without restrictions. (Ingredient(s) concerned: 'Chromium')

Pass with conditions - The maximum recommended daily dose of the medicine must not provide more than: (i) 15 mg of pyridoxine for children aged between 1 and 3 years (inclusive); (ii) 20 mg of pyridoxine for children aged between 4 and 8 years (inclusive); (iii) 30 mg of pyridoxine for children aged between 9 and 13 years (inclusive); (iv) 40 mg of pyridoxine for individuals aged 14 and 18 years (inclusive); and (v) 100 mg of pyridoxine for individuals aged 19 years and older. (Ingredient(s) concerned: 'Pyridoxine')

When for oral use and the total amount of sodium from all ingredients in the maximum daily dose is more than 120 mg, the medicine requires the following warning statement on the label: - (SODIUM) 'The recommended daily dose of this medicine contains [state quantity and units] of sodium' (or words to that effect). (Ingredient(s) concerned: 'Croscarmellose sodium')

PRODUCT DETAILS

Dosage Form:	Tablet, film coated
Route of Administration:	Oral
Maximum daily dose:	2

FORMULATION DETAILS

ACTIVE INGREDIENTS:

STANDARD

Ingredient:	Trigonella foenum-graecum 20 mg
Plant Part:	seed
Plant Preparation:	Extract dry concentrate
Ratio:	(125:1)
Equivalent Preparation:	Dry 2.5 g
Preparation Steps:	
Plant Preparation:	Extract dry concentrate (125:1)
Plant Preparation Step:	1
Solvents:	purified water 100%
Ingredient:	Gymnema sylvestre 400 mg
Plant Part:	leaf
Plant Preparation:	Extract dry concentrate
Ratio:	(20:1)
Equivalent Preparation:	Dry 8 g
Preparation Steps:	
Plant Preparation:	Extract dry concentrate (20:1)
Plant Preparation Step:	1
Solvents:	purified water 30%

Solvents:	ethanol 70%
Ingredient:	Nigella sativa 5 mg
Plant Part:	seed
Plant Preparation:	Extract dry concentrate
Ratio:	(10:1)
Equivalent Preparation:	Dry 50 mg
Preparation Steps:	
Plant Preparation:	Extract dry concentrate (10:1)
Plant Preparation Step:	1
Solvents:	ethanol 30%
Solvents:	purified water 70%
Ingredient:	Cynara scolymus 53.34 mg
Plant Part:	leaf
Plant Preparation:	Extract dry concentrate
Ratio:	(6:1)
Equivalent Preparation:	Dry 320.04 mg
Preparation Steps:	
Plant Preparation:	Extract dry concentrate (6:1)
Plant Preparation Step:	1
Solvents:	purified water 100%
Ingredient:	Petroselinum crispum 50 mg
Plant Part:	leaf
Plant Preparation:	Powder
Ingredient:	Taraxacum officinale 37.5 mg
Plant Part:	root
Plant Preparation:	Extract dry concentrate
Ratio:	(20:1)
Equivalent Preparation:	Dry 750 mg
Preparation Steps:	
Plant Preparation:	Extract dry concentrate (20:1)
Plant Preparation Step:	1
Solvents:	purified water 100%
Ingredient:	Apium graveolens 50 mg
Plant Part:	seed
Plant Preparation:	Powder
Ingredient:	chromium picolinate 200 microgram
Equivalents:	chromium 25 microgram
Ingredient:	pyridoxine hydrochloride 30 mg
Equivalents:	pyridoxine 24.7 mg

Ingredient: Laminaria digitata 50 mg
Plant Part: blade
Plant Preparation: Powder
Equivalents: iodine 149.9 microgram

EXCIPIENT INGREDIENTS:

STANDARD

Ingredient: maltodextrin
Ingredient: magnesium stearate
Ingredient: calcium hydrogen phosphate dihydrate
Ingredient: croscarmellose sodium
Ingredient: microcrystalline cellulose
Ingredient: colloidal anhydrous silica
Ingredient: crospovidone
Ingredient: povidone

PROPRIETARY INGREDIENTS

Ingredient: NutraShine Pink 8442-08-PT-S 64.75 mg
(PI number:143204)

MANUFACTURER DETAILS

Name: s47
Manufacturer ID:
Licence ID:
Location:
Manufacturing Steps:

Name: s47
Manufacturer ID:
Licence ID:
Location:
Manufacturing Steps:

Name: s47
Manufacturer ID:
Licence ID:
Location:
Manufacturing Steps:

Name: s47
Manufacturer ID:
Licence ID:

Location:
Manufacturing Steps:

s47

Name:
Manufacturer ID:
Licence ID:
Location:
Manufacturing Steps:

s47

Name:
Manufacturer ID:
Licence ID:
Location:
Manufacturing Steps:

s47

Name:
Manufacturer ID:
Licence ID:
Location:
Manufacturing Steps:

s47

Name:
Manufacturer ID:
Licence ID:
Location:
Manufacturing Steps:

s47

INDICATIONS & WARNINGS

Warning:

(VIT) Vitamins can only be of assistance if the dietary vitamin intake is inadequate. OR Vitamin...

(S) If symptoms persist consult your healthcare practitioner

(VITB6SX) WARNING - Stop taking this medication if you experience tingling, burning or numbness and see your healthcare practitioner as soon as possible. [Contains vitamin B6].

Application General

eBS Logo

Product Name:	Eir Women Show Up
Product Code:	Other products
Client Name:	HealthREG Solutions Group
Sponsor Name:	Ellkay Group Pty Ltd
Is this Application in response to a Section 30:	No
Can this product be used as a code stock:	No
This application is to:	create a new ARTG Entry
Submission Cost:	$870.00
Payment Exemption No:	
Application Status:	Completed
Application Type:	New (A new AUST L will be generated)
Validation Report:	5/04/2022 8:13:08 PM

Information Messages

Successful validation of this application is not to be considered as an indication that a medicine is compliant with the legislative requirements. The listed medicines validation system is a tool to assist sponsors in listing a medicine on the ARTG. Sponsors are expected to be aware of, and comply with, all relevant regulatory requirements for their listed medicine.

s47

[redacted]

For Information Only - Species listed on CITES - if exporting or importing this product please contact the Department of Sustainability, Environment, Water, Population and Communities by telephone (DSEWPaC) on 02 6274 1111, facsimile on 02 6274 1921, or email to wildlifetrade@environment.gov.au to determine whether Australia's wildlife legislation places any controls on this ingredient. Further information is available on the Department of Sustainability, Environment, Water, Population and Communities' Wildlife Trade and Conservation website: http://www.environment.gov.au/biodiversity/trade-use/index.html (Ingredient(s) concerned: 'Panax quinquefolius')

Pass with conditions: When the ingredient is in a medicine that is for internal use the following warning statement is required on the label: - (VAC) 'Vitex agnus-castus may affect hormones and medicines such as oral contraceptives. Consult your health professional before use' (or words to that effect). (Ingredient(s) concerned: 'Vitex agnus-castus')

The Ginkgo biloba leaf extract used in the manufacture of this medicine must comply with the requirement of Identification Test B of the monograph Powdered Ginkgo Extract in the United States Pharmacopeia 32 - National Formulary 27 (USP32-NF27), as in force or existing from time to time. This condition does not apply to powdered or dried leaf. (Ingredient(s) concerned: 'Ginkgo biloba')

Pass with conditions - The requirements specified in paragraphs (a) to (b) below apply to a medicine that contains the ingredient that is: - listed in the Register before 1 March 2022; and - released for supply before 1 March 2023. (a) The maximum recommended daily dose must provide no more than 200 mg of pyridoxine. (b) If the medicine contains more than 50 mg and no more than 200 mg of pyridoxine per maximum recommended daily dose the medicine requires the following warning statement on the medicine label: - (VITB6SX) 'WARNING - Stop taking this medication if you experience tingling, burning or numbness and see your healthcare practitioner as soon as possible. [Contains vitamin B6].' The requirements specified in paragraphs (c) to (d) below apply to a medicine that contains the ingredient that is: - listed in the Register on or after 1 March 2022; or - released for supply on or after 1 March 2023. (c) The maximum recommended daily dose of the medicine must not provide more than: (i) 15 mg of pyridoxine for children aged between 1 and 3 years (inclusive); (ii) 20 mg of pyridoxine for children aged between 4 and 8 years (inclusive); (iii) 30 mg of pyridoxine for children aged between 9 and 13 years (inclusive); (iv) 40 mg of pyridoxine for individuals aged 14 and 18 years (inclusive); and (v) 100 mg of pyridoxine for individuals aged 19 years and older. (d) If the maximum recommended daily dose of the medicine provides more than 10 mg of pyridoxine, the following warning statement is required on the medicine label: - (VITB6SX) 'WARNING - Stop taking this medication if you experience tingling, burning or numbness and see your healthcare practitioner as soon as possible. [Contains vitamin B6].' (Ingredient(s) concerned: 'Pyridoxine')

When for oral use and the total amount of sodium from all ingredients in the maximum daily dose is more than 120 mg, the medicine requires the following warning statement on the label: - (SODIUM) 'The recommended daily dose of this medicine contains [state quantity and units] of sodium' (or words to that effect). (Ingredient(s) concerned: 'Croscarmellose sodium')

PRODUCT DETAILS

Dosage Form:	Tablet, film coated
Route of Administration:	Oral

FORMULATION DETAILS

ACTIVE INGREDIENTS:

STANDARD

Ingredient:	Panax quinquefolius 25 mg
Plant Part:	root
Plant Preparation:	Extract dry concentrate
Ratio:	(20:1)
Equivalent Preparation:	Dry 500 mg
Preparation Steps:	
Plant Preparation:	Extract dry concentrate (20:1)
Plant Preparation Step:	1
Solvents:	Ethanol 65%
Solvents:	Water - purified 35%
Ingredient:	Vitex agnus-castus 50 mg
Plant Part:	fruit
Plant Preparation:	Extract dry concentrate
Ratio:	(20:1)

Equivalent Preparation:	Dry 1 g
Preparation Steps:	
Plant Preparation:	Extract dry concentrate (20:1)
Plant Preparation Step:	1
Solvents:	Ethanol 70%
Solvents:	Water - purified 30%
Ingredient:	Ginkgo biloba 30 mg
Plant Part:	leaf
Plant Preparation:	Extract dry concentrate
Ratio:	(50:1)
Equivalent Preparation:	Dry 1.5 g
Preparation Steps:	
Plant Preparation:	Extract dry concentrate (50:1)
Plant Preparation Step:	1
Solvents:	Ethanol 50%
Solvents:	Water - purified 50%
Ingredient:	ascorbic acid 125 mg
Ingredient:	thiamine hydrochloride 11.15 mg
Equivalents:	thiamine 9.94 mg
Ingredient:	riboflavin 12.5 mg
Ingredient:	nicotinamide 12.5 mg
Ingredient:	calcium pantothenate 12.5 mg
Equivalents:	pantothenic acid 11.45 mg
Ingredient:	pyridoxal 5-phosphate monohydrate 12.5 mg
Equivalents:	pyridoxine 7.98 mg
Ingredient:	cyanocobalamin 100 microgram

EXCIPIENT INGREDIENTS:

STANDARD

Ingredient:	hypromellose
Ingredient:	magnesium stearate
Ingredient:	calcium hydrogen phosphate dihydrate
Ingredient:	croscarmellose sodium
Ingredient:	microcrystalline cellulose
Ingredient:	colloidal anhydrous silica
Ingredient:	crospovidone
Ingredient:	povidone

PROPRIETARY INGREDIENTS

Ingredient: NutraShine Yellow 6687-91-PT-S 50.42 mg
(PI number:143212)

MANUFACTURER DETAILS

Name:
Manufacturer ID:
Licence ID:
Location:
Manufacturing Steps:

s47

Name:
Manufacturer ID:
Licence ID:
Location:
Manufacturing Steps:

s47

Name:
Manufacturer ID:
Licence ID:
Location:
Manufacturing Steps:

s47

Name:
Manufacturer ID:
Licence ID:
Location:
Manufacturing Steps:

s47

Name:
Manufacturer ID:
Licence ID:
Location:
Manufacturing Steps:

s47

Name:
Manufacturer ID:
Licence ID:
Location:
Manufacturing Steps:

s47

Name:

s47

Manufacturer ID:	s47
Licence ID:	
Location:	
Manufacturing Steps:	

INDICATIONS & WARNINGS

Warning:	(VAC) Vitex agnus-castus may affect hormones and medicines such as oral contraceptives. Consult your health professional before use' (or words to that effect). (VITMIN) Vitamins and minerals can only be of assistance if dietary intake is inadequate OR Vitamin and/or mineral supplements should not replace a balanced diet. (GEN2) If symptoms persist, seek the advice of a healthcare professional.
Subsection 26B(1) Notification:	For the purpose of subsection 26B(1) you are notifying the Secretary that a certificate under subsection 26B(1) is not required for this application.

Application General

eBS Logo

Product Name:	Eir Women Show Up
Product Code:	Other products
Client Name:	Ellkay Group Pty Ltd
Sponsor Name:	Ellkay Group Pty Ltd
Is this Application in response to a Section 30:	No
Can this product be used as a code stock:	No
This application is to:	change a current ARTG Entry
AUST L:	386939
Submission Cost:	$0.00
Payment Exemption No:	
Application Status:	Completed
Application Type:	Correction of ARTG Record
Validation Report:	24/08/2023 6:53:13 PM

Information Messages

Successful validation of this application is not to be considered as an indication that a medicine is compliant with the legislative requirements. The listed medicines validation system is a tool to assist sponsors in listing a medicine on the ARTG. Sponsors are expected to be aware of, and comply with, all relevant regulatory requirements for their listed medicine.

s47

For Information Only - Species listed on CITES - if exporting or importing this product please contact the Department of Sustainability, Environment, Water, Population and Communities by telephone (DSEWPaC) on 02 6274 1111, facsimile on 02 6274 1921, or email to wildlifetrade@environment.gov.au to determine whether Australia's wildlife

legislation places any controls on this ingredient. Further information is available on the Department of Sustainability, Environment, Water, Population and Communities' Wildlife Trade and Conservation website: http://www.environment.gov.au/biodiversity/trade-use/index.html (Ingredient(s) concerned: 'Panax quinquefolius')

Pass with conditions: When the ingredient is in a medicine that is for internal use the following warning statement is required on the label: - (VAC) 'Vitex agnus-castus may affect hormones and medicines such as oral contraceptives. Consult your health professional before use' (or words to that effect). (Ingredient(s) concerned: 'Vitex agnus-castus')

The Ginkgo biloba leaf extract used in the manufacture of this medicine must comply with the requirement of Identification Test B of the monograph Powdered Ginkgo Extract in the United States Pharmacopeia 32 - National Formulary 27 (USP32-NF27), as in force or existing from time to time. This condition does not apply to powdered or dried leaf. (Ingredient(s) concerned: 'Ginkgo biloba')

Pass with conditions - The maximum recommended daily dose of the medicine must not provide more than: (i) 15 mg of pyridoxine for children aged between 1 and 3 years (inclusive); (ii) 20 mg of pyridoxine for children aged between 4 and 8 years (inclusive); (iii) 30 mg of pyridoxine for children aged between 9 and 13 years (inclusive); (iv) 40 mg of pyridoxine for individuals aged 14 and 18 years (inclusive); and (v) 100 mg of pyridoxine for individuals aged 19 years and older. (Ingredient(s) concerned: 'Pyridoxine')

When for oral use and the total amount of sodium from all ingredients in the maximum daily dose is more than 120 mg, the medicine requires the following warning statement on the label: - (SODIUM) ‘The recommended daily dose of this medicine contains [state quantity and units] of sodium’ (or words to that effect). (Ingredient(s) concerned: 'Croscarmellose sodium')

PRODUCT DETAILS

Dosage Form:	Tablet, film coated
Route of Administration:	Oral
Maximum single dose:	2
Maximum daily dose:	2

FORMULATION DETAILS

ACTIVE INGREDIENTS:

STANDARD

Ingredient:	Panax quinquefolius 25 mg
Plant Part:	root
Plant Preparation:	Extract dry concentrate
Ratio:	(20:1)
Equivalent Preparation:	Dry 500 mg
Preparation Steps:	
Plant Preparation:	Extract dry concentrate (20:1)
Plant Preparation Step:	1
Solvents:	ethanol 65%
Solvents:	purified water 35%
Ingredient:	Vitex agnus-castus 50 mg
Plant Part:	fruit
Plant Preparation:	Extract dry concentrate
Ratio:	(20:1)

Equivalent Preparation:	Dry 1 g
Preparation Steps:	
Plant Preparation:	Extract dry concentrate (20:1)
Plant Preparation Step:	1
Solvents:	purified water 30%
Solvents:	ethanol 70%
Ingredient:	Ginkgo biloba 30 mg
Plant Part:	leaf
Plant Preparation:	Extract dry concentrate
Ratio:	(50:1)
Equivalent Preparation:	Dry 1.5 g
Preparation Steps:	
Plant Preparation:	Extract dry concentrate (50:1)
Plant Preparation Step:	1
Solvents:	ethanol 50%
Solvents:	purified water 50%
Ingredient:	ascorbic acid 125 mg
Ingredient:	thiamine hydrochloride 11.15 mg
Equivalents:	thiamine 9.94 mg
Ingredient:	riboflavin 12.5 mg
Ingredient:	nicotinamide 12.5 mg
Ingredient:	calcium pantothenate 12.5 mg
Equivalents:	pantothenic acid 11.45 mg
Ingredient:	pyridoxal 5-phosphate monohydrate 12.5 mg
Equivalents:	pyridoxine 7.98 mg
Ingredient:	cyanocobalamin 100 microgram

EXCIPIENT INGREDIENTS:

STANDARD

Ingredient:	hypromellose
Ingredient:	magnesium stearate
Ingredient:	calcium hydrogen phosphate dihydrate
Ingredient:	croscarmellose sodium
Ingredient:	microcrystalline cellulose
Ingredient:	colloidal anhydrous silica
Ingredient:	crospovidone
Ingredient:	povidone

PROPRIETARY INGREDIENTS

Ingredient: NutraShine Yellow 6687-91-PT-S 50.42 mg
(PI number:143212)

MANUFACTURER DETAILS

Name:
Manufacturer ID:
Licence ID:
Location:
Manufacturing Steps:

s47

Name:
Manufacturer ID:
Licence ID:
Location:
Manufacturing Steps:

s47

Name:
Manufacturer ID:
Licence ID:
Location:
Manufacturing Steps:

s47

Name:
Manufacturer ID:
Licence ID:
Location:
Manufacturing Steps:

s47

Name:
Manufacturer ID:
Licence ID:
Location:
Manufacturing Steps:

s47

Name:
Manufacturer ID:
Licence ID:
Location:
Manufacturing Steps:

s47

s47

Name:	s47
Manufacturer ID:	
Licence ID:	
Location:	
Manufacturing Steps:	

Name:	s47
Manufacturer ID:	
Licence ID:	
Location:	
Manufacturing Steps:	

INDICATIONS & WARNINGS

Warning:	(VAC) Vitex agnus-castus may affect hormones and medicines such as oral contraceptives. Consult your .....
	(VITMIN) Vitamins and minerals can only be of assistance if dietary intake is inadequate OR Vitamin and/or...
	(GEN2) If symptoms persist, seek the advice of a healthcare professional
	(VITB6SX) WARNING - Stop taking this medication if you experience tingling, burning or numbness and see your healthcare practitioner as soon as possible. [Contains vitamin B6].

Application General

eBS Logo

Product Name:	Eir Women Zipped
Product Code:	Other products
Client Name:	HealthREG Solutions Group
Sponsor Name:	Ellkay Group Pty Ltd
Is this Application in response to a Section 30:	No
Can this product be used as a code stock:	No
This application is to:	create a new ARTG Entry
Submission Cost:	$870.00
Payment Exemption No:	
Application Status:	Completed
Application Type:	New (A new AUST L will be generated)
Validation Report:	5/04/2022 8:14:57 PM

Information Messages

Successful validation of this application is not to be considered as an indication that a medicine is compliant with the legislative requirements. The listed medicines validation system is a tool to assist sponsors in listing a medicine on the ARTG. Sponsors are expected to be aware of, and comply with, all relevant regulatory requirements for their listed medicine.

s47

Gluten is a mandatory component of Maltodextrin where the ingredient is derived from gluten containing grains such as wheat, barley, rye and oats and must be declared in the application when the route of administration is other than Topical and Mucosal. Medicines containing gluten require the label statement GLUTEN 'Contains [insert name of ingredient]'. (Ingredient(s) concerned: 'Maltodextrin')

Chromium sourced from organic materials: Medicines are listable only if the maximum recommended daily dose provides 50 micrograms or less of chromium from organic sources (ie chromium picolinate, chromium nicotinate and 'High chromium yeast'). Chromium sourced from inorganic materials: listable without restrictions. (Ingredient(s) concerned: 'Chromium')

Pass with conditions - The requirements specified in paragraphs (a) to (b) below apply to a medicine that contains the

ingredient that is: - listed in the Register before 1 March 2022; and - released for supply before 1 March 2023. (a) The maximum recommended daily dose must provide no more than 200 mg of pyridoxine. (b) If the medicine contains more than 50 mg and no more than 200 mg of pyridoxine per maximum recommended daily dose the medicine requires the following warning statement on the medicine label: - (VITB6SX) 'WARNING - Stop taking this medication if you experience tingling, burning or numbness and see your healthcare practitioner as soon as possible. [Contains vitamin B6].' The requirements specified in paragraphs (c) to (d) below apply to a medicine that contains the ingredient that is: - listed in the Register on or after 1 March 2022; or - released for supply on or after 1 March 2023. (c) The maximum recommended daily dose of the medicine must not provide more than: (i) 15 mg of pyridoxine for children aged between 1 and 3 years (inclusive); (ii) 20 mg of pyridoxine for children aged between 4 and 8 years (inclusive); (iii) 30 mg of pyridoxine for children aged between 9 and 13 years (inclusive); (iv) 40 mg of pyridoxine for individuals aged 14 and 18 years (inclusive); and (v) 100 mg of pyridoxine for individuals aged 19 years and older. (d) If the maximum recommended daily dose of the medicine provides more than 10 mg of pyridoxine, the following warning statement is required on the medicine label: - (VITB6SX) 'WARNING - Stop taking this medication if you experience tingling, burning or numbness and see your healthcare practitioner as soon as possible. [Contains vitamin B6].' (Ingredient(s) concerned: 'Pyridoxine')

When for oral use and the total amount of sodium from all ingredients in the maximum daily dose is more than 120 mg, the medicine requires the following warning statement on the label: - (SODIUM) ‘The recommended daily dose of this medicine contains [state quantity and units] of sodium’ (or words to that effect). (Ingredient(s) concerned: 'Croscarmellose sodium')

PRODUCT DETAILS

Dosage Form:	Tablet, film coated
Route of Administration:	Oral
Maximum daily dose:	2

FORMULATION DETAILS

ACTIVE INGREDIENTS:

STANDARD

Ingredient:	Trigonella foenum-graecum 20 mg
Plant Part:	seed
Plant Preparation:	Extract dry concentrate
Ratio:	(125:1)
Equivalent Preparation:	Dry 2.5 g
Preparation Steps:	
Plant Preparation:	Extract dry concentrate (125:1)
Plant Preparation Step:	1
Solvents:	purified water 100%
Ingredient:	Gymnema sylvestre 400 mg
Plant Part:	leaf
Plant Preparation:	Extract dry concentrate
Ratio:	(20:1)
Equivalent Preparation:	Dry 8 g
Preparation Steps:	
Plant Preparation:	Extract dry concentrate (20:1)

Plant Preparation Step: 1

Solvents: Ethanol 70%

Solvents: Water - purified 30%

Ingredient: Nigella sativa 5 mg

Plant Part: seed

Plant Preparation: Extract dry concentrate

Ratio: (10:1)

Equivalent Preparation: Dry 50 mg

Preparation Steps:

Plant Preparation: Extract dry concentrate (10:1)

Plant Preparation Step: 1

Solvents: Ethanol 30%

Solvents: Water - purified 70%

Ingredient: Cynara scolymus 53.34 mg

Plant Part: leaf

Plant Preparation: Extract dry concentrate

Ratio: (6:1)

Equivalent Preparation: Dry 320.04 mg

Preparation Steps:

Plant Preparation: Extract dry concentrate (6:1)

Plant Preparation Step: 1

Solvents: purified water 100%

Ingredient: Petroselinum crispum 50 mg

Plant Part: leaf

Plant Preparation: Powder

Ingredient: Taraxacum officinale 37.5 mg

Plant Part: root

Plant Preparation: Extract dry concentrate

Ratio: (20:1)

Equivalent Preparation: Dry 750 mg

Preparation Steps:

Plant Preparation: Extract dry concentrate (20:1)

Plant Preparation Step: 1

Solvents: purified water 100%

Ingredient: Apium graveolens 50 mg

Plant Part: seed

Plant Preparation: Powder

Ingredient: chromium picolinate 200 microgram

Equivalents:	chromium 25 microgram
Ingredient:	pyridoxine hydrochloride 30 mg
Equivalents:	pyridoxine 24.7 mg
Ingredient:	Laminaria digitata 50 mg
Plant Part:	blade
Plant Preparation:	Powder
Equivalents:	iodine 149.9 microgram

EXCIPIENT INGREDIENTS:

STANDARD

Ingredient:	maltodextrin
Ingredient:	magnesium stearate
Ingredient:	calcium hydrogen phosphate dihydrate
Ingredient:	croscarmellose sodium
Ingredient:	microcrystalline cellulose
Ingredient:	colloidal anhydrous silica
Ingredient:	crospovidone
Ingredient:	povidone

PROPRIETARY INGREDIENTS

Ingredient:	NutraShine Pink 8442-08-PT-S 64.75 mg (PI number:143204)

MANUFACTURER DETAILS

Name:	s47
Manufacturer ID:	
Licence ID:	
Location:	
Manufacturing Steps:	

Name:	s47
Manufacturer ID:	
Licence ID:	
Location:	
Manufacturing Steps:	

Name:	s47
Manufacturer ID:	
Licence ID:	

Location:
Manufacturing Steps:

s47

Name:
Manufacturer ID:
Licence ID:
Location:
Manufacturing Steps:

s47

Name:
Manufacturer ID:
Licence ID:
Location:
Manufacturing Steps:

s47

Name:
Manufacturer ID:
Licence ID:
Location:
Manufacturing Steps:

s47

Name:
Manufacturer ID:
Licence ID:
Location:
Manufacturing Steps:

s47

INDICATIONS & WARNINGS

Warning:	(S) If symptoms persist consult your healthcare practitioner (or words to that effect). (VIT) Vitamins can only be of assistance if the dietary vitamin intake is inadequate. OR Vitamin supplements should not replace a balanced diet.
Subsection 26B(1) Notification:	For the purpose of subsection 26B(1) you are notifying the Secretary that a certificate under subsection 26B(1) is not required for this application.